Eli Lilly Total Non-Operating Income/Expense 2010-2024 | LLY

Eli Lilly annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • Eli Lilly total non-operating income/expense for the quarter ending September 30, 2024 was $-2.764B, a 7.8% decline year-over-year.
  • Eli Lilly total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.274B, a 90.01% decline year-over-year.
  • Eli Lilly annual total non-operating income/expense for 2023 was $0.097B, a 130.13% decline from 2022.
  • Eli Lilly annual total non-operating income/expense for 2022 was $-0.321B, a 59.18% increase from 2021.
  • Eli Lilly annual total non-operating income/expense for 2021 was $-0.202B, a 117.2% decline from 2020.
Eli Lilly Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $97
2022 $-321
2021 $-202
2020 $1,172
2019 $292
2018 $146
2017 $302
2016 $113
2015 $101
2014 $341
2013 $519
2012 $674
2011 $-179
2010 $-5
2009 $-230
Eli Lilly Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $-2,764
2024-06-30 $-633
2024-03-31 $27
2023-12-31 $3,096
2023-09-30 $-2,998
2023-06-30 $-37
2023-03-31 $36
2022-12-31 $260
2022-09-30 $-111
2022-06-30 $-119
2022-03-31 $-351
2021-12-31 $-77
2021-09-30 $-636
2021-06-30 $191
2021-03-31 $321
2020-12-31 $477
2020-09-30 $159
2020-06-30 $447
2020-03-31 $89
2019-12-31 $263
2019-09-30 $-25
2019-06-30 $-32
2019-03-31 $86
2018-12-31 $31
2018-09-30 $-2
2018-06-30 $47
2018-03-31 $70
2017-12-31 $113
2017-09-30 $50
2017-06-30 $60
2017-03-31 $78
2016-12-31 $213
2016-09-30 $27
2016-06-30 $21
2016-03-31 $-149
2015-12-31 $117
2015-09-30 $87
2015-06-30 $-196
2015-03-31 $93
2014-12-31 $205
2014-09-30 $57
2014-06-30 $54
2014-03-31 $25
2013-12-31 $31
2013-09-30 $-31
2013-06-30 $12
2013-03-31 $508
2012-12-31 $1
2012-09-30 $735
2012-06-30 $-17
2012-03-31 $-46
2011-12-31 $50
2011-09-30 $-83
2011-06-30 $-58
2011-03-31 $-88
2010-12-31 $74
2010-09-30 $-81
2010-06-30 $-46
2010-03-31 $48
2009-12-31 $587
2009-09-30 $-617
2009-06-30 $-129
2009-03-31 $-71
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94